ClinicalTrials.gg
WithdrawnNCT05644626Updated Nov 29, 2023

Safety, Pharmacokinetics and Antitumor Activity of BGB-B167 Alone and in Combination With Tislelizumab in Participants With Solid Tumors in Chinese Participants

A Phase 1 interventional study of BGB-B167 and Tislelizumab in Solid Tumors, sponsored by BeiGene. Withdrawn. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-11-29.

Sponsored by BeiGene · Phase 1, Interventional, and Treatment

Why this study was withdrawn
Sponsor determined the data was no longer needed.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
0
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study will evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of BGB-B167 monotherapy and in combination with tislelizumab (BGB-A317) in participants with select advanced solid tumors in Chinese participants

02

Conditions studied

  • Solid Tumors
03

In context

Lead sponsor

BeiGene is the lead sponsor of 125 studies on the registry; 2 are open to participants now.

Of its 55 completed or terminated interventional studies of FDA-regulated products, 32 (58%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with or cytologically confirmed unresectable locally advanced or solid tumors previously treated with standard systemic therapy or for whom treatment is not available, not tolerated, or refused, or not expected to provide significant clinical benefit or be tolerated in the medical judgement of the investigator
  • (ECOG) Performance Status ≤ 1
  • Adequate organ function as indicated by laboratory values during screening or ≤ 7 days before the first dose of study drug(s)
  • Women of must be willing to use a highly effective method of for the duration of the study
  • Nonsterile men must be willing to use highly effective method of birth control for the duration of the study

Exclusion criteria

Exclusion Criteria:

  • Active or uncontrolled, untreated
  • Active diseases or history of autoimmune diseases that may relapse
  • Any ≤ 3 years before the first dose of study drug(s) except for the specific cancer under investigation in this study and any locally recurring cancer that has been treated with curative intent
  • History of severe reactions to other monoclonal antibody products or their
  • Untreated chronic or chronic hepatitis B virus (HBV) carriers
  • Known history of infection.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Phase 1a: Dose Escalation

    Part A: Increasing dose levels of BGB-B167 monotherapy; Part B: Increasing dose levels of BGB-B167 in combination with tislelizumab (BGB-A317)

    Drug: BGB-B167 · Drug: Tislelizumab

  • Experimental
    Phase 1b: Dose Expansion

    BGB-B167 alone or in combination with tislelizumab (BGB-A317)

    Drug: BGB-B167 · Drug: Tislelizumab

Interventions

  • DrugBGB-B167

    Intravenous administration

  • Intravenous administration

    Also known as: BGB-A317

06

What researchers measure

Primary outcomes

  1. Phase 1a: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Time frame: Up to Approximately 30 months

  2. Phase 1a: Number of Participants Experiencing AEs Meeting Protocol-defined Dose-limiting Toxicity (DLT) Criteria

    Time frame: Up to Approximately 24 months

  3. Phase 1a: Maximum Tolerated Dose (MTD) of BGB-B167

    The maximum tolerated dose (MTD) is defined as the highest tolerated dose for which the estimated toxicity rate is closest to the target toxicity rate of 30%.

    Time frame: Approximately 30 months

  4. Phase 1a: Recommended Phase 2 doses (RP2Ds)

    RP2Ds of BGB-B167 alone or in combination with tislelizumab will be determined based on a biologically effective dose

    Time frame: Approximately 24 months

  5. Phase 1b: Objective Response Rate (ORR) as determined by investigators per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1

    ORR is defined as the proportion of participants who had confirmed complete response (CR) or partial response (PR).

    Time frame: Up to Approximately 30 months

Secondary outcomes

  1. Phase 1a: ORR

    ORR is defined as the proportion of participants who had confirmed complete response (CR) or partial response (PR) as determined by investigators per RECIST v1.1.

    Time frame: Up to Approximately 30 months

  2. Phase 1a and Phase 1b: Duration of Response (DOR) as determined by investigators per RECIST v1.1.

    DOR is defined as the time from the first determination of a confirmed objective response until the first documentation of progression or death due to any cause, whichever occurs first.

    Time frame: Up to Approximately 30 months

  3. Phase 1a and Phase 1b: Disease Control Rate (DCR) as determined by investigators per RECIST v1.1.

    DCR is defined as the proportion of participants with best overall response (BOR) of confirmed CR, PR, or stable disease

    Time frame: Up to Approximately 30 months

  4. Phase 1a and Phase 1b: Clinical Benefit Rate (CBR) as determined by investigators per RECIST v1.1.

    CBR is defined as the proportion of participants with BOR of confirmed CR, PR, or stable disease lasting ≥ 24 weeks.

    Time frame: Up to Approximately 30 months

  5. Phase 1b: Progression Free Survival (PFS) as determined by investigators per RECIST v1.1.

    PFS is defined as the time from the date of the first administration of study drug to the date of the first documentation of disease progression or death due to any cause, whichever occurs first.

    Time frame: Up to Approximately 30 months

  6. Phase 1a and Phase 1b: Maximum Serum Concentration (Cmax) of BGB-B167

    Time frame: Up to Approximately 30 months

  7. Phase 1a and Phase 1b: Minimum Observed Plasma Concentration (Cmin) of BGB-B167

    Time frame: Up to Approximately 30 months

  8. Phase 1a and Phase 1b: Time to Cmax (Tmax) of BGB-B167

    Time frame: Up to Approximately 30 months

  9. Phase 1a: Terminal half-life (t1/2) of BGB-B167

    Time frame: Up to Approximately 30 months

  10. Phase 1a: Area Under the Plasma Concentration-time curve (AUC0-7d) of BGB-B167

    Time frame: Up to Approximately 30 months

  11. Phase 1a: Clearance (CL) BGB-B167

    Time frame: Up to Approximately 30 months

  12. Phase 1a: Volume of Distribution at Steady State (Vss) of BGB-B167

    Time frame: Up to Approximately 30 months

  13. Phase 1a and Phase 1b: Number of Participants with Anti-Drug Antibodies (ADAs)

    Time frame: Up to Approximately 30 months

  14. Phase 1b: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Time frame: Up to Approximately 30 months

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Mar 2024; primary completion for Mar 2025, 12 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 1, 2022
First posted
Dec 9, 2022
StartEst.
Mar 2024
Primary completionEst.
Mar 2025
CompletionEst.
Aug 2025
Last update
Nov 29, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 29, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05644626
Lead sponsor
BeiGene
Responsible party
Sponsor
First posted
Dec 9, 2022
Start date
Mar 2024 (estimated)
Primary completion
Mar 2025 (estimated)
Completion
Aug 2025 (estimated)
Last update
Nov 29, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tislelizumab

Start the discussion